LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Eurofins Genomics Buys VBC-Biotech Businesses, Establishes Austrian Subsidiary

By LabMedica International staff writers
Posted on 18 Nov 2014
Eurofins Genomics (Ebersberg, Germany) has acquired VBC-Biotech's (Vienna, Austria) oligonucleotide synthesis and DNA sequencing businesses, and an Austrian subsidiary is being established.

Eurofins MWG Operon is an international provider of genomic services established around the core business lines next generation sequencing (NGS), custom DNA sequencing, oligonucleotides, siRNA, and gene synthesis. A team of experts and a broad range of technologies in the field of genomic services, forensics, agroscience, pharmaceutical, environmental, food and feed testing, underline the approach to offer best praxis solutions and versatile concepts.

Eurofins Genomics is the genomics division of the Eurofins Scientific Group. The Austrian subsidiary called Eurofins Genomics AT and headquartered in Vienna, will leverage Eurofins' global network, production capacity, and infrastructure. "The new direct presence in Austria will provide value to our customers by demonstration our commitment to this market," Eurofins Genomics AT Managing Director Siegfried Schnabl said in a statement. "Furthermore, Vienna will serve as a perfect hub for future business into Central and Eastern Europe and beyond."

The joint company is located in Vienna. All VBC-Biotech's services have been integrated into the Eurofins Genomics business units.

Financial and other terms of the deal were not disclosed.

Related Links:

Eurofins Genomics
VBC-Biotech's


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Radial Immunodiffusion Assay
Radial Immunodifusion - C3 ID
Laboratory Software
ArtelWare

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more